Despite the demonstration of potent immunosuppressive function of T cell receptor (TCR)-ab 1 double-negative regulatory T cells (DN T regs ), scarce numbers and lack of effective expansion method limit their clinical applications. Here we describe an approach that allows for $3500-fold exvivo expansion of human DN T regs within 3 weeks with > 97% purity. Exvivo-expanded DN T regs suppress proliferation of polyclonally stimulated autologous T and B cells in vitro through direct cell-to-cell contact.
Introduction
Allogeneic haematopoietic stem cell transplantation (HSCT) is an effective treatment of haematopoietic malignancies, but graft-versus-host disease (GVHD) remains a major complication and the leading cause of non-relapse mortality [1, 2] . Although patient survival has been improved in recent years, it is attributed mainly to advancements in the management of the symptoms rather than prevention of GVHD. Even though we now understand more clearly the pathophysiology, risk factors and diagnostics of GVHD, administration of immunosuppressive drugs remains a conventional treatment and prophylaxis of GVHD. However, the use of these drugs carries serious risks of infections and malignancies, as well as burdensome side effects. In order to minimize and eventually eliminate the need of pharmaceutical immunosuppression, extensive efforts have been made to explore the potential of immunotherapy using immune regulatory T cells (T regs ) to induce transplantation tolerance and inhibit GVHD.
T regs are a heterogeneous population of many subsets, which differ with respect to their origin and development, cell surface marker expression and mechanism of action.
The two specific types of T regs that have been used in the treatment or prophylaxis of GVHD with promising results were naturally occurring thymus-derived CD4 1 CD25
highforkhead box P3(FoxP3) 1 T regs (nT reg ) and extrythymically generated T regulatory type I (Tr1) cells [3] . Treatment of GVHD with T regs may be conducted by adoptive transfer of ex-vivo-expanded T regs [4] [5] [6] [7] [8] or via activation and proliferation of patients' T regs ; for example, by administration of a low dose of IL-2 [9] , treatment with Sirolimus and RGI-2001 [10] or infusion of demethylating agent 5-azacytidine (AZA) [11] . In the very first clinical trial, infusion of exvivo-expanded polyclonal T regs resulted in significant improvement in a chronic GVHD patient [4] . In subsequent trials, adoptive transfer of T regs has been shown to be relatively safe and efficacious in the reduction of incidence of GVHD [5] [6] [7] [8] . However, the success of T reg immunotherapies relies ultimately upon effective ex-vivo expansion of a highly pure, functional and stable cellular product [3] .
In addition to nT regs and Tr1 cells, double-negative (DN) T regs have been shown to have regulatory properties. DN T regs express T cell receptor (TCR)-ab 1 , are natural killer (NK) lineage marker-negative and lack CD4 and CD8 coreceptors on their cell surface [12] . Neither murine [12] [13] [14] nor human [15] DN T regs express the FoxP3 transcription factor. We and others have demonstrated in various rodent models that DN T regs were able to induce antigen-specific tolerance to allogeneic skin, heart and pancreas grafts and inhibit various infections and autoimmune diseases [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Furthermore, DN T regs were able to inhibit the onset of GVHD while mediating beneficial anti-leukaemia effects [20, 26] . Human DN T regs have also been shown to suppress allogeneic immune responses in vitro [15, 27, 28] . Their clinical significance has been highlighted in allogeneic HSCT patients, where a higher frequency of circulating DN T regs was associated with reduced severity of GVHD [29, 30] . These studies provide compelling evidence supporting the use of DN T regs in clinical settings. However, DN T regs constitute only 1% circulating T cells in both rodents and humans [12, 27] . Translation of DN T reg therapy to the clinic has been hindered by the lack of positive cell surface markers for selection and reliable expansion methods to produce sufficient numbers of functional DN T regs for in-vivo preclinical studies and, ultimately, clinical use.
In this study, we developed a novel protocol that allows for large-scale ex-vivo expansion of highly pure and functional population of human DN T regs . These ex-vivo-expanded DN T regs are effective suppressors of autologous CD4
1 and CD8
1
T cell proliferations, as well as B cells in vitro. Furthermore, we show for the first time in a humanized mouse model that the infusion of ex-vivo-expanded human DN T regs improved the outcome of xenogeneic GVHD significantly. The protective effect of DN T regs in vivo was enhanced further by in-vitro treatment of DN T regs with rapamycin. These findings emphasize the potential for clinical use of DN T regs poised to broaden T cell-based therapies in treatment of GVHD and prevention of allograft rejection.
Materials and methods

Cell isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors using Ficoll-Hypaque density gradient centrifugation. DN T regs were enriched from PBMCs by negative selection using magnetic cell sorting technology (MACS), according to the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany [31, 32] ) in the presence of rhIL-2 (250 U/ml) and rhIL-7 (10 ng/ml; PeproTech, Rocky Hill, NJ, USA). In some experiments DN T regs were treated with rapamycin (2 lM; Sigma, St Louis, MO, USA) for 2 h at 378C and washed extensively prior to functional assays. Purity of DN T regs was monitored by flow cytometry. If purity of DN T regs was < 90%, further purification was performed via magnetic bead separation.
Flow cytometry and antibodies
The following mAbs were used to label cells: FITCconjugated anti-CD4 (A161A1), anti-CD8 (HIT8a), anti-CD25 (BC96), anti-CD56 (HCD56), anti-CD127 (A019D5; Biolegend, San Diego, CA, USA), anti-TCR-gd (Beckman Coulter, Brea, CA, USA); phycoerythrin (PE)-conjugated anti-CD19 (HIB19), anti-CD62L (DREG-56; Biolegend), CD152 (14D3; eBioscience); PE-cyanin 7 (Cy7)-conjugated anti-CD3 (HIT3a), anti-CD56 (HCD56; Biolegend); peridinin chlorophyll (PerCP)/Cy5.5-conjugated anti-CD8 (HIT8a; Biolegend); allophycocyanin (APC)-conjugated anti-TCR-ab (IP26), anti-CD279 (eBioJ105; eBioscience); and APC-Cy7-conjugated anti-CD4 (RPA-T4; Biolegend). Cells were analysed phenotypically using multi-colour flow cytometry. Dead cells were excluded with either propidium iodide (Sigma-Aldrich, St Louis, MO, USA), 4 0 ,6-diamidino-2-phenylindole (DAPI) (Biolegend) or 7-aminoactinomycin D (7-AAD) (eBioscience). Fluorescence minus one (FMO) controls were used to identify the gates.
For intracellular cytokine staining, cells were activated with leucocyte activation cocktail in the presence of monensin (GolgiPlug; BD Pharminogen) for 4 h. After washing, cells were stained with fixable viability dye eFluor450 (eBioscience) for live/dead cell recognition, stained for surface proteins, fixed and permeabilized, and finally stained for intracellular cytokines. Data were acquired using LSR II (Becton Dickinson) or Accuri C6 (Accuri Cytometers, Ann Arbor, MI, USA) instruments and analysed using FlowJo version 10 software (Tree Star, Inc., Ashland, OH, USA).
Suppression assays
The suppressor capacity of expanded DN T regs was determined in a suppression assay, as described previously [33, 34] . Briefly, purified CD4 Mice and xenogeneic GVHD model
) mice (Jackson Laboratories) were bred in the specific pathogen-free colony in the Animal Research Facility at University Health Network (UHN). To induce xenogeneic GVHD, 6-8-week-old mice received whole-body sublethal irradiation (250 cGy) from the 137 Cs source 24 h prior to tail vein injection with 5 3 10 6 human PBMCs on day 0. Treated mice received either one or three injections of 10 7 autologous DN T regs on day 0 or days 0, 3 and 7, respectively. In some experiments, DN T regs were preincubated with rapamycin prior to their use. As a control, a group of mice received a single injection of 10 7 DN T regs alone. All mice were monitored daily for the signs of GVHD, such as weight loss, hunched posture, ruffling of the fur, diarrhoea and reduced mobility. At the time of severe GVHD, defined by weight loss greater than 20% of initial weight or the presence of two or more symptoms described above, mice were killed in accordance with local animal welfare regulations, and the end-point of survival was recorded.
Flow-based lymphocyte cytotoxicity assay
Target cells were harvested, labelled with PKH26 (SigmaAldrich), washed and co-cultured either alone or in the presence of varying ratios of DN T regs . After 24 h, annexin V expression on target cells was determined by flow cytometry and specific killing was calculated using the formula:
% Specif ic killing5100 
Statistical analysis and ethics statement
Graphical presentation and statistical analysis of data were performed using Prism version 6 (GraphPad, San Diego, CA, USA). All results are presented as means 6 standard deviation (s.d.), unless specified otherwise. Survival analysis was performed using the log-rank test. Other data were assessed for normal distribution and variance compared between two groups using Student's t-test or analysis of variance (ANOVA) for multiple group comparisons. A P-value of less than 0Á05 was considered statistically significant. Human blood samples were collected from healthy donors after obtaining written informed consent and used according to University Health Network (UHN) Research Ethics Board-approved protocols (05-0221-T). Animal studies were approved by UHN Animal Care Committee (Protocol no. 741.22), and carried out according to the Canadian Council on Animal Care Guidelines.
Results
Isolation and expansion of DN T regs from peripheral blood
Previous studies showed that human DN T regs could be obtained from apheresis samples by stimulating purified DN T regs with allogeneic myeloid dendritic cells for in-vitro studies [15, 27, 28] . However, due to the lack of an effective method for large-scale expansion, the in-vivo function of human DN T regs remains unclear. In order to study the function of human DN T regs in vivo and to determine the feasibility of using DN T regs as a new adoptive immunotherapy, we developed a novel protocol that allows for large-scale expansion of polyclonal human DN T regs (Fig. 1a) . First, the DN T reg population was enriched by depleting CD4
1 , CD8 1 , TCR-gd 1 and CD56 1 cells from
PBMCs of healthy donors. The enriched DN T regs , which constituted approximately 4% of total cells at the start of the culture (d0), were activated by plate-bound anti-CD3 antibody. Activated DN T regs were then expanded in the presence of aAPCs along with rhIL-2 and rhIL-7. Using this protocol, DN T regs expanded 3422 6 2341-fold (Fig. 1b ) after 3 weeks of co-culture. The frequency of DN T regs in peripheral blood varies among different individuals. However, from 100 ml of blood we were able to produce up to 1 3 10 9 DN T regs after 3 weeks. The average purity of ex-vivo-expanded DN T regs was 95Á48 6 2Á49% (n 5 8, Fig. 1c ). This protocol generates sufficient numbers of a highly pure population of human DN T regs for in-vivo functional studies and can be optimized further in future for clinical applications.
Phenotypical characterization of the ex-vivo-expanded human DN T regs
To characterize expanded DN T regs , we analysed various phenotypical markers associated commonly with T reg cells. Similar to conventional human CD4 T regs , expanded DN T regs did not express inhibitory molecules, cytotoxic T lymphocyte antigen (CTLA)-4 or programmed death (PD)-1 ( Fig. 2b) .
To reveal the profile of soluble factors produced by DN T regs , we analysed supernatants of ex-vivo-expanded polyclonal DN T regs by performing a multiplex assay for 27 different cytokines and chemokines. Resting ex-vivo- expanded DN T regs produced very low levels of IL-6, IL-9 and IL-13. Upon stimulation with phorbol myristate acetate (PMA)/ionomycin, DN T regs produced higher amounts of IL-4, IL-6, IL-9, IL-10 and IL-13 but lower amounts of proinflammatory T helper type 1 (Th1) cytokines interleukin (IL)-2, interferon (IFN)-g and tumour necrosis factor (TNF)-a in comparison to conventional T cells (T conv ) (Fig. 2c) . These data suggest that DN T regs differ from nT regs , Tr1 or T conv cells in their expression of a unique set of cell-surface markers and cytokines at resting and/or activation state.
Ex-vivo-expanded DN T regs suppress proliferation of T cells and B cells in a cell contact-dependent mechanism
To determine whether ex-vivo-expanded DN T regs manifest suppressive function, we evaluated the ability of DN T regs to inhibit proliferation of autologous CD4
1 and CD8 1 T cells, as well as CD19 1 B cells. Upon CD3 and CD28 stimulation, more than 95% of responder T cells proliferated within 5 days (Fig. 3a) . However, addition of DN T regs induced a dose-dependent suppression of both CD4 1 and CD8 1 T cell proliferation ( Fig. 3a and b) . Similarly, DN T regs also suppressed proliferation of CD19 1 B cells in a dose-dependent manner (Fig. 3c) . Together, these data indicate that ex-vivoexpanded DN T regs are effective at inhibiting proliferation of autologous B cells and CD4 1 and CD8 1 T cells in vitro. IL-10 has been shown to be an important mediator for Tr1 and regulatory B cells [35, 36] . The multiplex analysis has shown that DN T regs produced significantly more IL-10 in comparison to T conv cells activated and expanded from the same donor. However, neutralizing IL-10 with antibody did not reduce significantly the ability of DN T regs to suppress the proliferation of autologous CD4 1 T cells (Fig. 4a) or CD8 1 T cells (Fig. 4b) . These results suggest that production of IL-10 is not a major mechanism of DN T regmediated suppression. Furthermore, we investigated whether cell-to-cell contact is crucial for DN T reg -mediated suppression using a Transwell assay. When DN T regs and CD4 1 (Fig. 4c ) or CD8 1 (Fig. 4d ) responder cells were separated by a membrane but both populations were cocultured with aCD3/CD28 beads, no proliferation of the responder cells was observed. Additionally, we examined whether any soluble factors that are released only upon interaction of DN T regs with the responder cells would promote the suppression. To this end, DN T regs were co-cultured with the responder cells and aCD3/CD28 beads in the upper chamber, but no inhibition of proliferation of the responder cells in the lower chamber was observed (Fig. 4c,d ). Murine DN T regs were shown to be able to suppress immune responses via direct cytolysis [12, 14, 19, 21, 25, 37, 38] . To determine whether DN T regs are cytotoxic to autologous cells, activated CD4 1 cells or freshly isolated autologous PBMCs were used as targets and co-cultured with DN T regs at varying ratios. No DN T reg -mediated cytotoxicity against autologous cells was observed, even though DN T regs effectively killed allogeneic leukaemic MV4-11 cells (Fig. 4e) .
Adoptive transfer of ex-vivo-expanded DN T regs delays onset of xenogeneic GVHD
The in-vivo function of human DN T regs has not been studied previously. To determine whether ex-vivo-expanded human DN T regs can suppress an immune response in vivo, we adapted a xenogeneic GVHD model by infusion of human PBMCs into immune-deficient NSG mice (Fig. 5a ) [39, 40] . As expected, after infusion of 5 3 10 6 human PBMCs, immune-deficient NSG mice developed severe acute GVHD, characterized by rapid weight loss and death with a median survival time (MST) of 19 days (Fig. 5b,c) . In contrast, infusion of 10 7 DN T regs alone did not cause weight loss in any of the recipient mice and all mice survived beyond 80 days (P < 0Á001; Fig. 5b,c) . More importantly, mice that received human PBMCs followed by the treatment with three doses of 10 7 DN T regs had delayed onset of GVHD and significantly prolonged survival compared to the non-DN T reg treated group (MST 5 28 days; P < 0Á01; Fig. 5b ). DN T reg -treated recipients were also significantly less affected by weight loss compared to the PBMC group (P < 0Á05; Fig. 5c ). These data indicate that adoptive transfer of DN T regs alone did not induce xenogeneic GVHD and can attenuate the severity of xenogeneic GVHD induced by infusion of human PBMCs.
Rapamycin augments immunosuppressive function of DN T regs in vitro and in vivo
Rapamycin (sirolimus, RAPA) is a mechanistic target of rapamycin (mTOR) inhibitor that has been shown to facilitate expansion and promote the function of nT regs and iT regs in mice and humans [41] . Allgauer et al. found that activation of the protein kinase B (Akt)/mTOR pathway by IL-7 abrogated the immunosuppressive function of human alloantigen-specific DN T regs [28] . As our protocol calls for addition of IL-7 during DN T reg expansion, we investigated whether the inhibition of mTOR pathway by RAPA could further enhance the immunosuppressive function of DN T regs . To this end, ex-vivo-expanded DN T regs were incubated in the presence of RAPA for 2 h, washed extensively and used in a 3-day suppression assay. Blockade of the mTOR pathway by RAPA rendered DN T regs more immunosuppressive, as they inhibited proliferation of both autologous CD4
1 and CD8 1 T cells to a greater extent than non-RAPA-treated DN T regs (Fig. 6a-c) .
To evaluate further whether RAPA can augment the suppressive function of DN T regs in vivo, we used the same xenogeneic GVHD mouse model as described earlier. to their injection protected mice from GVHD significantly and increased their survival time by 78% (MST 5 32 days) when compared to PBMC controls (MST 5 18 days; P < 0Á001). In addition to prolonged survival, one injection of RAPA-treated DN T regs also protected mice from weight loss significantly in comparison to the PBMC-only group (P < 0Á05, Fig. 6e ), whereas one injection of non-RAPA-treated DN T regs had no significant effect on weight loss or survival (MST 5 20 days) in comparison to the untreated group. Together, these data indicate that pretreatment of DN T regs with RAPA renders them more immunosuppressive both in vitro and in vivo. 
Discussion
In spite of demonstration of the potent immunosuppressive function of murine DN T regs for nearly 20 years [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] , the in-vivo function of human DN T regs remains elusive. Mackensen's group was the first to isolate and characterize human DN T regs in vitro [27] . They purified human DN T regs by magnetic beads followed by in-vitro stimulation with allogeneic dendritic cells (DCs) in the presence of exogenous IL-2. This approach produced antigen-specific DN T regs that effectively suppressed CD4 played an important part in the initial induction of DN T regs . Consistent with this idea, aCD3/CD28 beads failed to expand DN T regs adequately (data not shown), suggesting the need for other co-stimulatory signals. Subsequently, DN T regs were expanded in the presence of artificial APCs, a K562 cell line with surface expression of transduced anti-CD3 antibody, as well as co-stimulatory molecules CD80, CD83, CD86 and 4-1BBL [31, 32] , which provided sufficient stimulation for DN T reg activation and proliferation. In addition to supplementing with IL-2, we found that addition of IL-7 to the co-culture from day 7 onwards increased the yield and suppressive function of DN T regs significantly in comparison to DN T regs co-cultured solely in IL-2 (Supporting information, Fig. S1 ). A recent report from Mackensen's group showed that the addition of IL-7 to the suppression assay increased proliferation of human alloantigen-specific DN T regs , but hampered their suppressive function due to hyperactivation of the Akt/mTOR pathway [28] . However, we found that supplementation of exogenous IL-7 during the suppression assay did not have any effect on the function of DN T regs expanded devoid of IL-7 (Supporting information, Fig. S2 ). The discrepancy between our results and the report by Allgauer et al. could be because of different expansion procedures between the two studies and suggest that IL-7 may have a differential effect, depending on the culture conditions and/or presence of other cells. The mTOR inhibitor rapamycin has been shown to increase the suppressive capacity of nT regs and iT regs , as well as enhance generation of iT regs [41] . Allgauer et al. found that the IL-7 induced impaired function of DN T regs could be restored by a 2-h treatment with mTOR inhibitors [28] . Consistent with this finding, we found that a 2-h incubation of the expanded DN T regs with rapamycin prior to the suppression assay increased the suppressive function of DN T regs significantly. Although our approach to grow DN T regs may seem counterintuitive, considering the results, we found that the addition of IL-7 to the expansion culture promoted proliferation and survival, thus increasing the yield and quality of the end product. Mice that lost > 20% of their initial weight were euthanized. Survival and weight change data were pooled from three experiments and statistical differences between different groups were analysed using Log-rank and analysis of variance (ANOVA) tests, respectively. *P < 0Á05. **P < 0Á01 ***P < 0Á001. Similar results were observed in three independent experiments. (d,e) Sublethally irradiated NSG mice were injected i.v. with 5 3 10 6 peripheral blood mononuclear cells (PBMCs) (n 5 28) to induce GVHD without further treatment. Experimental mice were infused with PBMCs followed by one injection of 10 7 either untreated DN T regs (n 5 19) or 10 7 RAPA-treated DN T regs (n 5 9). Survival of recipient mice is shown in (d) and body weight change is shown in (e). Log-rank and analysis of variance (ANOVA) tests were used to determine the statistical significance in survival and weight changes, respectively between different groups *P < 0Á05; **P < 0Á01; ***P < 0Á001; n.s. 5 non-significant.
Previous studies showed that human DN T regs activated by allogeneic DCs or aCD3/CD28 beads can effectively suppress autologous CD4 1 and CD8 1 T cells in vitro [15, 27, 28] . Correspondingly, ex-vivo-expanded polyclonal DN T regs also suppressed proliferation of autologous CD4 1 
and CD8
1 T cells stimulated with aCD3/CD28 beads. Furthermore, these polyclonal DN T regs are capable of inhibiting autologous CD19 1 B cell proliferation, which is consistent with the findings in murine DN T regs [13, 42] . The dose-dependent suppression of B cells opens doors for a wider application of DN T regs in the clinic, as autoreactive B cells mediate many autoimmune diseases [43] . Whether DN T regs also hamper B cell activation, class-switching or antibody production should be determined in the future.
Multiple studies have reported that murine DN T regs are able to suppress autologous T cells and B cells by direct cytolysis through Fas/FasL interaction or via the perforin/ granzyme pathway [12, 14, 19, 21, 25, 37, 38] . However, there are conflicting results regarding whether human DN T regs mediate suppression by elimination of the responder T cells [15, 27] . Annexin V staining of the responder cells isolated from the suppression assay did not reveal a decrease in the viability of CD4
1 T cells or CD8 1 T cells upon addition of DN T regs (Supporting information, Fig. S3 ). Furthermore, the results from the cytotoxicity assays revealed that DN T regs are not cytotoxic towards activated PBMCs despite their ability of killing the allogeneic leukaemic MV4-11 cell line. These data suggest that ex-vivo-expanded human DN T regs do not suppress autologous T cells via direct cytolysis.
DN T regs exhibit a unique cytokine production profile that differs from that of conventional T cells. Consistent with the previous analysis of the cytokine profile of human [20, 21] and murine [25, 27] DN T regs , we revealed high production of IFN-g and limited production of IL-4, IL-5 and IL-10 by expanded human DN T regs . However, upon strong non-specific stimulation, DN T regs produced significantly more IL-10 than conventional T cells. Given that IL-10 played a significant role in the murine DN T reg -mediated suppression [25, 44, 45] , we evaluated the effect of neutralizing IL-10 in the suppression assay. Blocking IL-10 during the suppression assays had a minimal effect on the DN T reg -mediated suppression. Furthermore, we showed that polyclonal DN T regs require cell-to-cell contact to mediate suppression, as the presence of the Transwell membrane prevented suppression of the responder cells, indicating that immunosuppression is unlikely to be dependent upon IL-10 or other soluble factors. Furthermore, the addition of exogenous IL-2 or IL-7 to the suppression assay failed to abolish DN T reg regulatory function, suggesting that, unlike nT regs , they do not suppress by consumption of IL-2 (Supporting information, Fig. S2 ).
Several studies have demonstrated the therapeutic effect of murine DN T regs in treating GVHD [20, 44, 46] . Furthermore, retrospective clinical studies showed that the progress and severity of GVHD were correlated negatively with the frequency of DN T regs in peripheral blood after HSCT [29, 30] , suggesting a potentially therapeutic benefit of human DN T regs . To simulate clinical settings we adapted a xenogeneic GVHD model to study the function of DN T regs in vivo. We demonstrate that the infusion of ex-vivoexpanded human DN T regs attenuated xenogeneic GVHD instigated by the infusion of human PBMC into immunodeficient mice. DN T reg -treated subjects manifested significantly prolonged survival and less weight loss. The precise mechanisms by which DN T regs suppress xenogeneic GVHD remain elusive. By tracking the infused DN T regs in vivo, we found that DN T regs were present not only in the lymphoid organs such as blood, bone marrow and spleen, but also were able to home to GVHD target organs including liver and lungs, and remained there for at least 10 days (Supporting information, Fig. S4 ). Furthermore, we showed that DN T regs suppressed significantly the proliferation of T cells and B cells in vitro and our preliminary study suggested a decrease in the absolute number of CD4 1 and CD8 1 T cells in the recipients after DN T reg treatment (data not shown). Together, these data suggest that DN T regs may suppress the proliferation of effector cells in lymphoid and nonlymphoid organs. Importantly, the infusion of DN T regs into NSG mice did not cause xenogeneic GVHD, unlike the infusion of PBMCs. This unresponsiveness of DN T regs to xenogeneic antigens may be ascribed to the absence of TCR coreceptors, CD4 and CD8, on the cell surface, which may be an important feature in the clinical applications of DN T regs . Further studies are needed to elucidate the mechanisms involved in suppression of GVHD by DN T regs .
It is noted that DN T regs provided only a temporary protection from GVHD, as all the treated subjects eventually developed symptoms of GVHD. The lack of absolute prevention of onset of the disease may be attributed to the inability of the infused human DN T regs to persist in the immunodeficient mice without provision of human cytokines. As we and others have shown that DN T reg -mediated suppression is cell contact-and dose-dependent, and does not involve elimination of the responder T cells [15] , we propose that the magnitude of in-vivo suppression mediated by DN T regs may be directly dependent upon the number of DN T regs available. Consistent with this suggestion, one injection of DN T regs was insufficient to delay the onset of GVHD significantly, but three injections during a 1-week period reduced the severity of GVHD significantly and delayed the disease onset by 10 days. Compared to nT regs , however, a higher ratio of DN T regs to PBMCs was required to achieve the same efficacy [47, 48] . We speculate that this might be due to the differences in the mechanisms of suppression, or the ability of different T reg subtypes to survive/persist in vivo. Further investigations to unravel the requirements for DN T reg survival and function in vivo, as well as their mechanisms of action, will help to improve therapeutic efficacy of DN T regs .
Extensive efforts have been made to generate therapeutic levels of antigen-specific T regs , including DN T regs , for clinical use without great success. All clinical trials involved in the treatment or prophylaxis of GVHD to date used polyclonally activated T regs and showed promising clinical outcome [3] . Although polyclonal T regs may be less effective than antigen-or allospecific T regs on a per cell basis, the ability to produce large quantities of the readily available and stable off-the-shelf product should help to overcome this hurdle [49] . Furthermore, we found that pretreatment of DN T regs with rapamycin rendered DN T regs more immunosuppressive in vitro, and one dose of rapamycin-treated DN T regs protected mice to comparable levels as treatment with three doses of untreated DN T regs . These findings indicate that pretreatment of DN T regs with rapamycin enhances DN T reg suppressive function significantly, which minimizes the amount of DN T regs required to protect recipients from GVHD. It remains unclear how the short treatment of DN T regs with rapamycin resulted in a longlasting augmentation of DN T reg suppressive function. As rapamycin disrupts the Akt/mTOR pathway that governs proliferation, survival and metabolism, one possibility is that incubation of DN T regs with rapamycin may induce an anergy-like state in DN T regs , as suggested previously [28] . Similarly to what has been observed in other T reg types, this anergy-like state may be associated with increased regulatory function [50] . However, further studies are needed to determine the precise mechanisms by which rapamycin enhances the DN T reg function. In addition, whether infusion of higher and/or more doses of rapamycin-treated DN T regs would halt GVHD progression entirely, and whether combining DN T regs infusion with rapamycin would be more effective than infusion of DN T regs alone, will also need to be studied. Together, these findings have important implications for the future use of DN T regs in the clinic.
In summary, the ability to generate large numbers of stable and functional human DN T regs not only makes it possible, for the first time, to study their function in vivo, but also demonstrates the feasibility of using ex-vivo-expanded human DN T regs as an adoptive immunotherapy for the treatment of GVHD, which ultimately may reduce the need for pharmaceutical immunosuppression, thus minimizing side effects and drug-related toxicity.
Supporting information
Additional Supporting information may be found in the online version of this article at the publisher's web-site: Fig. S4 . Tracking and in-vivo proliferation of human lymphocytes in non-obese diabetic-scid IL2rg 2/2 ) (NSG) mice. Freshly isolated peripheral blood mononuclear cells (PBMCs) or ex-vivo-expanded double-negative regulatory T cells (DN T regs ) were stained with carboxyfluorescein succinimidyl ester (CFSE) and injected into sublethally irradiated (250 cGy) NSG mice. On days 1, 3, 5, 7 and 10, two to three mice per group were killed, and the following tissues were harvested: peripheral blood (PB), bone marrow (BM), spleen, lungs, kidneys and liver. Proliferative capacity of lymphocytes was assessed by CFSE dilution (a) and the frequency of human CD45
1 CD3
1 cells from each tissue was assessed by flow cytometry (b).
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